Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Black Diamond Therapeutics (BDTX) Current Assets (2018 - 2025)

Black Diamond Therapeutics' Current Assets history spans 6 years, with the latest figure at $132.4 million for Q4 2025.

  • For Q4 2025, Current Assets rose 30.9% year-over-year to $132.4 million; the TTM value through Dec 2025 reached $132.4 million, up 30.9%, while the annual FY2025 figure was $132.4 million, 30.9% up from the prior year.
  • Current Assets reached $132.4 million in Q4 2025 per BDTX's latest filing, down from $139.0 million in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $297.3 million in Q1 2021 to a low of $101.2 million in Q4 2024.
  • Average Current Assets over 3 years is $167.8 million, with a median of $139.0 million recorded in 2025.
  • Peak YoY movement for Current Assets: fell 28.2% in 2021, then soared 31.04% in 2025.
  • A 3-year view of Current Assets shows it stood at $241.5 million in 2021, then plummeted by 58.11% to $101.2 million in 2024, then soared by 30.9% to $132.4 million in 2025.
  • Per Business Quant, the three most recent readings for BDTX's Current Assets are $132.4 million (Q4 2025), $139.0 million (Q3 2025), and $146.7 million (Q2 2025).